Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
03/09/2025 16:47
Sept 3 (Reuters) - Biophytis SA ALBPS.PA: BIOPHYTIS SA: OBTAINS EMA AUTHORIZATION TO LAUNCH ITS PHASE 2 CLINICAL TRIAL IN OBESITY - SEC FILING Source text: [ID:n0001104659-25-086790] Further company coverage: ALBPS.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon